Ono and Medarex Enter Into Collaborative Research Agreement

Ono Pharmaceutical and Medarex announced that they have entered into a collaborative research agreement to research and develop a fully human anti-PD-1 antibody for the potential treatment of cancer. The parties have already started generating fully human anti-PD-1 antibody product candidates under Ono's intellectual property regarding PD-1 and using Medarex's proprietary UltiMAb Human Antibody Development System, and they expect that clinical studies could begin in 12 to 24 months.

PR Newswire

(http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/05-12-2005/0003596999&EDATE=)